Skip to main content
. 2024 May 23;16(6):827. doi: 10.3390/v16060827

Figure 3.

Figure 3

Relationship between the infection efficiency and the amount of SeV-HN protein in the V/HN-LV particles. (A) Schematic diagram of the production of LV particles using the modified SeV-HN-expressing plasmids. A 2:1:1 ratio of transfer, packaging, and VSV-G/Rev plasmids, and variable amounts of SeV-HN plasmids (unmodified HN, Kozak HN, or Kozak human codon-optimized HN), were used for the optimization of dual-pseudotyped LV particles. (B) The biological and physical titers of LVs. The bar graphs represent TU/mL, and the triangles represent PP/mL. The ratio of TU to PP is shown above each set of LV titers. (C) HEK293FT cells were infected with LV particles at 200 PP/cell, and the infection efficiency was determined by flow cytometry 2 days after transduction. (D) Ultracentrifuged LV particles were subjected to western blotting using VSV-G, whole SeV, and HIV1 p24 antibodies. Data are expressed as the mean ± SD with technical replicates (n = 3) and ordinary one-way ANOVA with Tukey post-hoc test. **** p < 0.0001; ns, not significant.